ReviewAsthma research and practice2021
Asthma and COVID-19: a dangerous liaison?
Review in Asthma research and practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Significant Production of Serum and Mucosal Anti-Spike-IgA Antibodies After Vaccine-Encoded or SARS-CoV-2-Infection-Induced Spike-Exposures in Patients with Asthma Treated with Monoclonal Antibodies Compared to Conventional Therapy.Journal of asthma and allergy · 2026Article
- Review
- Eosinophils and COVID-19: Insights into immune complexity and vaccine safety.Clinical and translational allergy · 2025Review
- Knowledge Mapping of COVID-19 and Asthma/Allergic Rhinitis: A Visual and Bibliometric Analysis.Journal of asthma and allergy · 2025Article
- Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- Asthma May Not be a Potential Risk Factor for Severe COVID-19 Illness: A Scoping Review.Environmental health insights · 2024Article
- Prioritizing Asthma Treatment Drugs through Multicriteria Decision Making.International journal of analytical chemistry · 2024Article
- Acute Pain and Development of Opioid Use Disorder: Patient Risk Factors.Current pain and headache reports · 2023Review
- COVID-19 in Patients with Chronic Lung Disease.Clinics in chest medicine · 2023Review
- Care by general practitioners for patients with asthma or COPD during the COVID-19 pandemic.NPJ primary care respiratory medicine · 2023Article
- The impact of the 2019/2020 Australian landscape fires on infant feeding and contaminants in breast milk in women with asthma.International breastfeeding journal · 2023Article
- Pleiotropic Functions of Nitric Oxide Produced by Ascorbate for the Prevention and Mitigation of COVID-19: A Revaluation of Pauling's Vitamin C Therapy.Microorganisms · 2023Review
- Omalizumab may protect allergic patients against COVID-19: A systematic review.The World Allergy Organization journal · 2023Review
- Adult Severe Asthma Registries: A Global and Growing Inventory.Pragmatic and observational research · 2023Article
- Identification of Comorbidities, Genomic Associations, and Molecular Mechanisms for COVID-19 Using Bioinformatics Approaches.BioMed research international · 2023Article
- A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma.Advances in therapy · 2022Article
- Spending Time with Mothers as a Resource for Children with Chronic Diseases: A Comparison of Asthma, Type 1 Diabetes, and Cancer during COVID-19 Pandemic.International journal of environmental research and public health · 2022Article
- Environmental contributions to the interactions of COVID-19 and asthma: A secondary publication and update.The World Allergy Organization journal · 2022Review
- Viral Infection and Airway Epithelial Immunity in Asthma.International journal of molecular sciences · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provoked the most striking international public health crisis of our time. COVID-19 can cause a range of breathing problems, from mild to critical, with potential evolution to respiratory failure and acute respiratory distress syndrome. Elderly adults and those affected with chronic cardiovascular, metabolic, and respiratory conditions carry a higher risk of severe COVID-19. Given the global burden of asthma, there are well-founded concerns that the relationship between COVID-19 and asthma could represent a "dangerous liaison".Here we aim to review the latest evidence on the links between asthma and COVID-19 and provide reasoned answers to current concerns, such as the risk of developing SARS-CoV-2 infection and/or severe COVID-19 stratified by asthmatic patients, the contribution of type-2 vs. non-type-2 asthma and asthma-COPD overlap to the risk of COVID-19 development. We also address the potential role of both standard anti-inflammatory asthma therapies and new biological agents for severe asthma, such as mepolizumab, reslizumab, and benralizumab, on the susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.